Recommendations for the development of rare disease drugs using the accelerated approval pathway and for qualifying biomarkers as primary endpoints (Q30624174)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Recommendations for the development of rare disease drugs using the accelerated approval pathway and for qualifying biomarkers as primary endpoints |
scientific article |
Statements
Recommendations for the development of rare disease drugs using the accelerated approval pathway and for qualifying biomarkers as primary endpoints (English)
1 reference
Emil D Kakkis
1 reference
Mary O'Donovan
1 reference
Gerald Cox
1 reference
Mark Hayes
1 reference
Federico Goodsaid
1 reference
P K Tandon
1 reference
Pat Furlong
1 reference
Susan Boynton
1 reference
Mladen Bozic
1 reference
May Orfali
1 reference
Mark Thornton
1 reference
10 February 2015
4 references
30 June 2019
1 September 2020
7 February 2024
4 references
30 June 2019
1 September 2020
7 February 2024
3 references
30 June 2019
1 September 2020
7 February 2024
1 reference
Identifiers
1 reference